AbbVie ABBV is set to report first-quarter 2026 results on April 29, before the opening bell. While the immunology segment is ...

Iovance Biotherapeutics is positioned for multi-year growth, with Amtagvi sales and pipeline momentum accelerating. Read why IOVA stock is a Buy.

BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.

Biodesix enters this update cycle with its fair value price target holding steady at US$30.00, as the latest estimate matches the prior US$30.00 figure. That stability sits against a backdrop of mixed ...

Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks 50,000 advanced NSCLC diag ...

Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high probabili ...

Johnson & Johnson (NYSE:JNJ) Q1 2026 Earnings Call Transcript April 14, 2026 Johnson & Johnson beats earnings expectations. Reported EPS is $2.7, expectations were $2.68. Operator: Good morning, and ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2026 Earnings Conference Call. [Operator Instructions] This call is being recorded. [Operator Instructions] I will now turn the call over ...

It’s been a little over two months since President Donald Trump’s direct-to-consumer pharmaceutical site, TrumpRx, launched, ...

The Bulls N’ Bears ASX Runner of the Week is… Bison Resources, which exploded on debut, as punters piled into its prime ...

The clock isn’t going to slow down. The system isn’t going to fix itself. Here’s how clinicians are finding a way to live — ...

BioNTech partners with Boehringer Ingelheim on lung cancer combo therapy, advances malaria vaccine, and plans capital raise to fund 15 Phase 3 oncology trials by 2026.